Stockscreener 앱 받기
493.11
9.83%
-53.77
시간 외 거래:
492.00
-1.11
-0.23%
전일 마감가:
$546.88
열려 있는:
$505.55
하루 거래량:
1.49M
Relative Volume:
4.63
시가총액:
$11.37B
수익:
$1.13B
순이익/손실:
$-309.44M
주가수익비율:
-38.52
EPS:
-12.8001
순현금흐름:
$-275.41M
1주 성능:
-9.25%
1개월 성능:
-8.16%
6개월 성능:
+0.78%
1년 성능:
+70.11%
1일 변동 폭
$447.01
$510.55
1주일 범위
$447.01
$566.18
52주 변동 폭
$290.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
493.11 | 12.71B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
481.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
738.34 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.58 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.17 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
322.08 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 24.82% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com
Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily
Madrigal Expands Rezdiffra Patent Portfolio Into 2045 - MyChesCo
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739 - Moomoo
Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions - Investing.com Nigeria
Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 - The Manila Times
Guojin Securities: The MASH sector is seeing intensive, multi‑dimensional catalysts come to fruition, and Madrigal is expected to maintain double-digit growth over the long term. - Moomoo
Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542 - Moomoo
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Pipeline Moves - Yahoo Finance
Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio - BioBuzz
Madrigal receives three new U.S. patents for resmetirom drug - Investing.com
Madrigal receives three new U.S. patents for resmetirom drug By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance I - GuruFocus
New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care - Stock Titan
Madrigal Grants Equity Awards to Seven New Employees - MyChesCo
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down - Quiver Quantitative
3 Under-the-Radar Stocks to Buy and Hold - Yahoo Finance
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey
5 Best Under-the-Radar Stocks to Invest In - Insider Monkey
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews
Madrigal gives seven new employees stock awards to join the company - Stock Titan
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
5.02%
자본화:
|
볼륨(24시간):